Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis

dc.contributor.author
Sosa Díaz, Lilian Elisa
dc.contributor.author
Calpena Campmany, Ana Cristina
dc.contributor.author
Silva Abreu, Marcelle
dc.contributor.author
Espinoza, Lupe Carolina
dc.contributor.author
Rincón, María
dc.contributor.author
Bozal de Febrer, Núria
dc.contributor.author
Domènech Cabrera, Òscar
dc.contributor.author
Rodríguez Lagunas, María José
dc.contributor.author
Clares Naveros, Beatriz
dc.date.issued
2020-05-06T20:50:53Z
dc.date.issued
2020-05-06T20:50:53Z
dc.date.issued
2019-07-03
dc.date.issued
2020-05-06T20:50:53Z
dc.identifier
1999-4923
dc.identifier
https://hdl.handle.net/2445/158997
dc.identifier
691101
dc.identifier
31277267
dc.description.abstract
The present study was designed to develop a thermoreversible gel of Pluronic (P407) loaded amphotericin B (AmB-gel) for the dermal and vaginal treatment of candidiasis. P407 was used as a copolymer to exploit potential advantages related to increasing drug concentration in the tissue layer in order to provide a local effect. Parameters including internal structure, swelling, porosity, and short-term stability were determined. In addition, drug release profile and ex vivo skin and vaginal permeation studies were carried out. Antifungal efficacy was evaluated against strains of Candida spp. and atomic force microscopy (AFM) supported the results. The tolerance of AmB-gel was studied by evaluating biomechanical properties of skin and determining the irritation level in scarified rabbit skin supported by histological analysis. Results confirmed the development of a thermoreversible AmB-gel with high porosity exhibiting Newtonian behavior at 4 °C and pseudoplasticity at 32 °C as well as optimal stability for at least 90 days. The Amb-gel provided a sustained drug release following a Boltzmann sigmoidal model. Non permeation was observed in skin and vaginal mucosa, showing a high retained amount of AmB of 960.0 and 737.3 µg/g/cm2, respectively. In vitro antifungal efficacy showed that AmB-gel was more effective than Free-AmB in inhibiting strains of Candida spp. and these results were corroborated by AFM. Finally, tolerance studies showed that its application did not induce skin irritation nor alter its biophysical properties. Together, these results confirmed that AmB-gel could be proposed as a promising candidate for the clinical status in the treatment of skin and vaginal candidiasis.
dc.format
18 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11070312
dc.relation
Pharmaceutics, 2019, vol. 11, num. 7, p. 312
dc.relation
https://doi.org/10.3390/pharmaceutics11070312
dc.rights
cc-by (c) Sosa Díaz, Lilian Elisa et al., 2019
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject
Candidiasi
dc.subject
Copolímers
dc.subject
Gels (Farmàcia)
dc.subject
Candidiasis
dc.subject
Copolymers
dc.subject
Gels (Pharmacy)
dc.title
Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)